Message to Our Shareholders

Commitment is the word that comes to mind when I look back at 2022 and all that we accomplished as a team. For the first time in our history, we were able to honor our commitment and deliver a transformative therapy to patients with the potential to change how generalized myasthenia gravis (gMG) is treated.

It was also our first opportunity to show our ability to execute commercially in the same way we have in developing breakthrough pipeline candidates. We had an ambitious task before us to launch VYVGART globally and bring our first-in-class immunology innovation to people living with gMG. We are proud to say we accomplished what we set out to do, thanks to the unwavering commitment demonstrated by our team of Argonauts.